Cleveland Diagnostics, a startup developing blood tests for a variety of cancers, just raised about $2 million, according to regulatory filing.
The company spun out of Cleveland Clinic Innovations in 2013, and hasn’t announced much since. Here’s MedCity‘s take on what the startup was up to at the time:
The new company is scooping up cancer diagnostic technology developed by Analiza Dx and combining it with technology from the Clinic to create new blood-based tests for cancer.
The technology is unique in that it measures changes to the structure of certain proteins in the blood that result from the presence of disease, explained Arnon Chait, who led Analiza Dx and will become CEO of Cleveland Diagnostics. “Instead of offering very expensive tools, like genetic analysis for example, we use a more common and low-cost approach (ELISA) to look at things that matter.”
By “things that matter,” he means actual changes to the structure of proteins, rather than the presence or concentration of those proteins in the blood. Because cancer is by nature a mutative disease, this approach makes more sense, he said.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The funding came from eight investors, according to the filing. Waiting on a call back from Cleveland Diagnostics to see what they’re working on; stay tuned.
[Image courtesy of Flickr user rosemary]
